• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.正在接受其他治疗的 COVID-19 患者，在使用目前提议用于 COVID-19 治疗的药物时，可能会发生药物-药物相互作用。
Fundam Clin Pharmacol. 2020 Oct;34(5):530-547. doi: 10.1111/fcp.12586. Epub 2020 Jul 24.
2
Interactions of recommended COVID-19 drugs with commonly used psychotropics.推荐的新冠病毒治疗药物与常用精神药物的相互作用。
Asian J Psychiatr. 2020 Aug;52:102173. doi: 10.1016/j.ajp.2020.102173. Epub 2020 May 21.
3
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.
4
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
5
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.新冠病毒疾病（COVID-19）患者使用羟氯喹的精神科影响
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
6
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.抗病毒药物治疗 SARS-CoV-2 的药代动力学/药效学及其与药物和其他支持措施的潜在相互作用：欧洲抗菌药物研究协会抗感染药物 PK/PD 研究组的综合评价。
Clin Pharmacokinet. 2020 Oct;59(10):1195-1216. doi: 10.1007/s40262-020-00924-9.
7
[Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].[关于法国在新冠疫情期间精神药物及其对精神障碍患者适应性的信息]
Encephale. 2020 Jun;46(3S):S14-S34. doi: 10.1016/j.encep.2020.04.006. Epub 2020 May 4.
8
The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.潜在治疗药物对新冠肺炎感染患者QT间期的影响：密切监测和纠正电解质的重要性。
Med Hypotheses. 2020 Oct;143:109847. doi: 10.1016/j.mehy.2020.109847. Epub 2020 May 16.
9
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
10
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.

引用本文的文献

1
COVID-19 management in patients with comorbid conditions.合并症患者的 COVID-19 管理。
World J Virol. 2025 Jun 25;14(2):102674. doi: 10.5501/wjv.v14.i2.102674.
2
Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects.新型冠状病毒肺炎与结核病药物之间的药物相互作用：细胞色素P450和转运体介导作用的综合综述
Pharmaceuticals (Basel). 2024 Aug 6;17(8):1035. doi: 10.3390/ph17081035.
3
Predicting anti-SARS-CoV-2 activities of chemical compounds using machine learning models.使用机器学习模型预测化合物的抗SARS-CoV-2活性。
Artif Intell Chem. 2023 Dec;1(2). doi: 10.1016/j.aichem.2023.100029. Epub 2023 Nov 19.
4
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.细胞色素 P450 2C9 在 COVID-19 治疗中的作用：现状与未来方向。
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24.
5
Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）住院患者治疗中的药物不良反应和药物相互作用
Antimicrob Steward Healthc Epidemiol. 2021 Oct 28;1(1):e38. doi: 10.1017/ash.2021.196. eCollection 2021.
6
Impact of the Drug Resistance Gene on the Risk Factors of Patients with COVID-19 and Its Relationship with the Drugs Used.耐药基因对新型冠状病毒肺炎患者危险因素的影响及其与所用药物的关系
Infect Drug Resist. 2022 May 24;15:2661-2669. doi: 10.2147/IDR.S358389. eCollection 2022.
7
Various Aspects of Non-Invasive Ventilation in COVID-19 Patients: A Narrative Review.《COVID-19 患者的无创通气的各个方面：叙述性综述》
Iran J Med Sci. 2022 May;47(3):194-209. doi: 10.30476/ijms.2021.91753.2291.
8
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).新冠病毒感染者中奈玛特韦/利托那韦药物相互作用的管理：法国药理学和治疗学学会（SFPT）指南。
Therapie. 2022 Sep-Oct;77(5):509-521. doi: 10.1016/j.therap.2022.03.005. Epub 2022 Apr 20.
9
Tools supporting polypharmacy management in Italy: Factors determining digital technologies' intention to use in clinical practice.意大利支持多药治疗管理的工具：决定数字技术在临床实践中使用意愿的因素。
Health Sci Rep. 2022 May 19;5(3):e647. doi: 10.1002/hsr2.647. eCollection 2022 May.
10
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.用于改善新冠病毒疾病治疗的药物遗传学和精准医学方法。
Front Pharmacol. 2022 Feb 18;13:835136. doi: 10.3389/fphar.2022.835136. eCollection 2022.

本文引用的文献

1
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
2
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
3
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?2019冠状病毒病与羟氯喹-阿奇霉素联合用药：我们应该为患者冒这个险吗？
Br J Clin Pharmacol. 2020 Jun;86(6):1176-1177. doi: 10.1111/bcp.14335. Epub 2020 May 7.
4
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.移植受者感染 SARS-CoV-2 的药物治疗：治疗药物监测和药物相互作用的考虑因素。
Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761.
5
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
6
High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）需要有创机械通气患者中肥胖的高患病率。
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199. doi: 10.1002/oby.22831. Epub 2020 Jun 10.
7
Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score.COVID-19 肺炎患者进展风险预测：CALL 评分。
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399. doi: 10.1093/cid/ciaa414.
8
Baricitinib for COVID-19: a suitable treatment?巴瑞替尼用于治疗新冠肺炎：一种合适的治疗方法？
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
9
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.法匹拉韦：药代动力学与对 2019 新型冠状病毒感染临床试验的关注。
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
10
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.严重新型冠状病毒肺炎与非新型冠状病毒肺炎患者凝血功能特征的差异。
J Thromb Thrombolysis. 2021 May;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.

正在接受其他治疗的 COVID-19 患者，在使用目前提议用于 COVID-19 治疗的药物时，可能会发生药物-药物相互作用。

Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.

机构信息

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.

INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.

出版信息

Fundam Clin Pharmacol. 2020 Oct;34(5):530-547. doi: 10.1111/fcp.12586. Epub 2020 Jul 24.

DOI:10.1111/fcp.12586
PMID:32603486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7361515/
Abstract

Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.

摘要

患有 COVID-19 的患者有时已经在接受一种或多种其他慢性疾病的治疗，尤其是如果他们是老年人。对于门诊或更严重病例住院治疗的 COVID-19 患者，引入一种治疗方法会引发潜在的药物相互作用的问题。在这里，我们分析了最常见的慢性疾病药物和目前作为 COVID-19 治疗或正在进行治疗试验的药物联合使用的潜在或已证实的风险。在可能的情况下提供了实用建议。